
    
      This will be an open label Phase IIb dose-finding, randomized, controlled study with a
      duration of 16 weeks of experimental therapy of Delpazolid(DZD) - Bedaquiline/Delamanid/
      Moxifloxacin (BDM) in adult patients with newly diagnosed, smear positive, uncomplicated,
      drug sensitive pulmonary tuberculosis (TB) to evaluate the safety, efficacy, tolerability,
      pharmacokinetics and exposure/response-relationship of different doses of delpazolid in
      combination with bedaquiline, delamanid and moxifloxacin.

      Participants will be randomized to one of five arms containing BDM standard dose with
      different doses of DZD.
    
  